Search Within

Karen Anne Autio

Formats
  1. Meeting Abstract (77)
  2. Journal Article (40)
  3. Review (3)
Groups
  1. Department of Medicine (120)
  2. Genitourinary Oncology Service (120)
  3. Solid Tumor Oncology Division (120)
  4. Hematologic Malignancies, Division of (30)
  5. GSK Faculty (21)
  6. Epidemiology and Biostatistics (14)

More Groups

People
  1. Howard Scher (46)
  2. Michael Morris (36)
  3. Dana Rathkopf (34)
  4. Susan Slovin (28)
  5. Daniel Danila (22)
  6. Wassim Abida (15)

More People

Years
  1. 2025 (5)
  2. 2024 (6)
  3. 2023 (7)
  4. 2022 (7)
  5. 2021 (7)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (48)
  2. Annals of Oncology (18)
  3. Journal for ImmunoTherapy of Cancer (11)
  4. Clinical Cancer Research (8)
  5. Journal of Immunotherapy and Precision Oncology (3)
  6. Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (50)
  2. Oxford University Press (18)
  3. Biomed Central Ltd (11)
  4. American Association for Cancer Research (10)
  5. Elsevier Inc. (5)
  6. Elsevier Science, Inc. (5)

More Publishers

Results (120)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the international registry for men with advanced prostate cancer
    Journal Article

    Chen, N.; McGrath, C. B.; Ericsson, C. I.; Vaselkiv, J. B.; Rencsok, E. M.; Stopsack, K. H.; Guard, H. E.; Autio, K. A.; Rathkopf, D. E.; Enting, D.; more...
    Cancer Epidemiology Biomarkers and Prevention (2024)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US
    Journal Article

    Rencsok, E. M.; Slopen, N.; Autio, K.; Morgans, A.; McSwain, L.; Barata, P.; Cheng, H. H.; Dreicer, R.; Heath, E.; McKay, R. R.; more...
    Quality of Life Research (2023)

    Fulltext@MSK | Save
  • A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)
    Meeting Abstract

    Autio, K. A.; Kyriakopoulos, C.; Xiao, H.; Emamekhoo, H.; Danila, D. C.; Devitt, M. E.; Riedel, E.; Jan, M.; Scher, H. I.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical impact of a rapid genetic testing model for advanced prostate cancer patients
    Journal Article

    Breen, K. E.; Symecko, H.; Spielman, K.; Gebert, R.; Shah, I. H.; Pundock, S.; Batson, M.; Narayan, V. K.; Stadler, Z. K.; Autio, K. A.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Autio, K. A.; Higano, C. S.; Nordquist, L.; Appleman, L. J.; Zhang, T.; Zhu, X. H.; Babiker, H.; Vogelzang, N. J.; Prasad, S. M.; Schweizer, M. T.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
    Journal Article

    Postel-Vinay, S.; Lam, V. K.; Ros, W.; Bauer, T. M.; Hansen, A. R.; Cho, D. C.; Stephen Hodi, F.; Schellens, J. H. M.; Litton, J. K.; Aspeslagh, S.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer
    Journal Article

    Truong, H.; Breen, K.; Nandakumar, S.; Sjoberg, D. D.; Kemel, Y.; Mehta, N.; Lenis, A. T.; Reisz, P. A.; Carruthers, J.; Benfante, N.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 porter platform trial in metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Shotts, K.; Howes, T.; Yu, J.; Densmore, J.; Da Silva, D.; Kumar, D.; Santulli-Marotto, S.; Cabanski, C.; Eisenbeisz, E.; Ivison, G.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Clinical and pharmacodynamic biomarker results from porter, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Galsky, M.; Autio, K.; Wentzel, K.; Graff, J.; Friedlander, T.; Densmore, J.; Cabanski, C.; Shotts, K.; Howes, T.; Yu, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save